ERBB2 and cancer: In Supplementary Figures S1 and S2, our results show that NIR-PIT using either the HER2 Affibody-IR700Dye conjugate or the trastuzumab-IR700Dye conjugate induced morphological changes of bursting as well as necrotic cell death of only HER2-positive cancer cells without any damage to HER2-negative cancer cells.